Dupilumab, a dual IL-4 and IL-13 inhibitor, was originally developed for the treatment of severe asthma, but has been repurposed for use in chronic obstructive pulmonary disease,28 with preliminary reports of benefit in non-CF bronchiectasis.29 Here, IL13 is linked to cystic fibrosis.